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Summary Background: Patients with the obesity-hypoventilation syndrome (OHS)
benefit from non-invasive ventilatory support. We assessed the long-term physio-
pathological response to 12-months of nocturnal ventilatory assistance at home with
bi-level positive airway pressure (BiPAP) via nasal mask in patients with this disease.
Methods: A series of 13 non-consecutive patients diagnosed of OHS (5 men and 8
women) with a mean (SD) age of 61.9 (8) years, underwent the following studies
before (baseline) and after 12 months of non-invasive domiciliary mechanical
ventilation: arterial blood gases, nocturnal digital pulse oximetry, spirometry, body
plethysmography, maximum muscular respiratory pressures and ventilatory pattern
with measurement of occlusion pressure (P0.1) before and after hypercapnia. An
overnight cardiorespiratory polygraphy was done at baseline.
Results: After 12 months of non-invasive mechanical ventilation, there were
significant (Po0:05) reductions of arterial carbon dioxide tension (PaCO2) and
increases in arterial oxygen tension, forced vital capacity and ventilatory response
to hypercapnia, as measured by the relationship between changes of P0.1 and PaCO2
(DP0.1/DPaCO2) as well as respiratory minute volume (VE) and PaCO2
(DVE=DPaCO2). Changes of the PaCO2 correlated significantly with those in the
(DP0.1/DPaCO2) slope (r ¼ 0:576; Po0:05).
Conclusions: The present results confirm that non-invasive home mechanical
ventilation is an effective approach for long-term treatment of OHS.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
Obesity-hypoventilation syndrome (OHS) is a term
used to describe obese patients who hypoventilate,
particularly during sleep, but do not have serious
neuromuscular or pulmonary disease.1 Although the
cause of this disorder is unclear, a central origin
alone or in association with the influence of
mechanical alterations of obesity upon the chest
wall and the respiratory system has been postu-
lated.2 Recently, OHS has been considered a
ventilation control disorder, with a decreased
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sensitivity of the respiratory centres to chemical
stimuli especially hypercapnia.3
Nocturnal ventilatory assistance is well estab-
lished as an effective approach to the treatment of
OHS.4 The mechanisms underlying the beneficial
effects of ventilatory assistance are probably
multifactorial, but recovery of the chemoreceptor
sensitivity as a result of improvements in gas
exchange seems to play an important pathophysio-
logical role.5 This 1-year uncontrolled trial was
therefore conducted to assess the long-term
physiopathological response to nocturnal ventila-
tory assistance at home with bi-level positive
airway pressure (BiPAP) via nasal mask in patients
with OHS.
Patients and methods
A 1-year prospective uncontrolled trial of home
mechanical ventilation in patients diagnosed of
OHS was designed. Eligible patients were those
with a body mass index (BMI) greater than 30 kg/m2
who met one (or both) of the following criteria:
daytime hypercapnia (arterial carbon dioxide ten-
sion [PaCO2] at rest 46.67 kPa), or nocturnal
hypercapnia defined as PaCO246.67 kPa in the
presence of arterial oxygen saturation (SaO2)
o90% (digital pulse oximetry) during more than
30% of the night, together with history of at least
one episode of respiratory failure that required in-
patient care. Patients with gas exchange altera-
tions due to other conditions, such as bronchiecta-
sis, fibrosis of the pleural space (fibrothorax),
obstructive sleep apnoea syndrome, neuromuscular
disease and chronic obstructive pulmonary disease
(COPD) were excluded. All participants were fully
informed on the studies to be performed before
and after non-invasive home mechanical ventila-
tion and written informed consent was obtained.
The study protocol was approved by the institu-
tional review board of the participating hospitals.
Before (baseline) and after 12 months of non-
invasive domiciliary mechanical ventilation, day-
time and nocturnal blood gases, nocturnal oximetry
and respiratory function studies were performed in
all patients. Respiratory function tests included
spirometry, body plethysmography, measurement
of maximum muscular inspiratory pressure and
ventilatory pattern, with determination of occlu-
sion pressure (P0.1) before and after an hypercap-
nic stimulus. An overnight cardiorespiratory
polygraphy was done at baseline.
Daytime arterial blood gases were measured with
the subject breathing room air and at rest, both at
the onset of the study as well as at 12 months of
follow-up. In all the cases, the blood was drawn when
the patient was sitting, after having remained at rest
for 10min, prior to the performance of any pulmon-
ary function maneuver. In patients having long-term
oxygen therapy indication, the oxygen was removed
30min before the measurement of blood gases. For
nocturnal blood gases, samples were drawn at 6:00
AM waking the patient for this measurement. Day-
time and nocturnal samples were routinely processed
in a gas analyser (Electrode Analicer IL-1306, Instru-
mental Laboratory, Lexinton, MA, USA) according to
recommendations of the Spanish Society of Pneumol-
ogy and Thoracic Surgery.6 Nocturnal oximetry was
performed using a portable device (Ohmeda 4700
Oxicap, Louisville, CO, USA). The cardiorespiratory
polygraphy was performed at the hospital using a
portable ambulatory device (Apnoescreen II plus,
Erich Jaeger, GmbH & CoKG, Wuerzburg, Germany)
that has been previously validated in adult subjects.7
Spirometry and plethysmographic manoeuvres were
performed with the patient in a sitting position with
the nose occluded by a nose clip, according to
recommendations of the European Respiratory So-
ciety8 using one MasterLab Pro unit (Erich Jaeger).
The maximum, inspiratory (Pimax) and expiratory
(Pemax) pressures were measured from the residual
volume and total lung capacity, respectively, with a
manometer (163 Sibelmed, Sibel, Barcelona, Spain)
following the method of Black and Hyatt.9 Measure-
ment of occlusion pressure (P0.1) and ventilatory
parameters were also performed with a MasterLab
Pro equipment (Erich Jaeger) according to the
method described by Whitelaw and associates.10
The rebreathing technique described by Read11 was
used for assessing the ventilatory response to
hypercapnia.
Once the initial tests were performed, if the
patient was considered suitable for inclusion in the
study, non-invasive ventilatory assistance with
BiPAP (Respironics Inc., Murrysville, PA, USA) via
nasal mask was used. Initial setting of 16 cm H2O
inspiratory positive airway pressure (IPAP) was then
adjusted to improve PaCO2 taking into account the
optimal comfort for the patient. Expiratory positive
airway pressure (EPAP) was set at 5 cm H2O in all
patients. Nine patients received supplemental
oxygen therapy; oxygen delivery was adjusted to
obtain SaO2 greater than 90%.
Mechanical ventilation was started at the hospi-
tal with a daytime adaptation period of 2 h. To
assess ventilatory treatment effectiveness, arterial
blood gases were measured at the beginning and at
the end of the session. After assessing patient’s
tolerance and daytime arterial blood gases re-
sponse, ventilatory support was then established
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for the sleep period, the effectiveness of which was
confirmed by nocturnal oximetry and measurement
arterial blood gases in the early morning. Patients
were then discharged from the hospital and
included in a home mechanical ventilation pro-
gramme. After a 12-month follow-up period, base-
line studies except for cardiorespiratory polygraphy
were repeated using the same techniques.
Statistical analysis
Descriptive data are expressed as mean (standard
deviation, SD). The Student’s t-test for paired data
was used to compare quantitative variables. Pear-
son’s product–moment correlation coefficient was
calculated to assess the relationship between
continuous variables. Statistical significance was
set at Po0:05: The Statistical Package for the
Social Sciences (SPSS, version 9.0, for Windows)
was used for the analysis of data.
Results
A total of 13 non-consecutive patients with OHS
were included in the study. There were 5 men and 8
women with a mean age of 61.9 (8.0) years (range
49–77). There were no significant differences
between data obtained at baseline and at the end
of the study for BMI and weight (Table 1). All
patients had an apnoea–hypopnoea index (AHI)
o10 (mean 4.8 [2.1], range 29). Daytime hyper-
capnia was recorded in five patients and nocturnal
hypercapnia in the remaining eight. At baseline,
nine patients required oxygen therapy due to an
arterial oxygen tension (PaO2) o8 kPa. No signifi-
cant correlations were found between daytime
PaCO2 and body weight (r ¼ 0:111) or BMI
(r ¼ 010).
Forced expiratory volume in 1 s (FEV1) was470%
of the predicted value in all patients, with a mean
of 77.6 (12.4)%; forced vital capacity ranged from
64% to 103% of the predicted value (mean 80.8
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Table 1 Characteristics of patients and comparison between measurements at baseline and 1-year after home
mechanical ventilation.
Parameter Baseline End of the study P value
Demographics
Men/women 5/8
Age, years 61.9 (8.0)
Anthropometric data
Body mass index, BMI (kg/m2) 42.2 (7.8) 41.5 (7.2) NS
Pulmonary function
Forced expiratory volume in 1 s, FEV1 (%) 77.6 (12.4) 86.6 (22.2) NS
Forced vital capacity, FVC (%) 80.8 (12.7) 92.6 (14.5) o0.05
Functional residual capacity, FRC (%) 94.3 (21.5) 98.4 (30.3) NS
Residual volume, RV (%) 127 (43.0) 116 (43.4) NS
Total lung capacity, TLC (%) 96.0 (14.6) 98.3 (19.6) NS
Maximum inspiratory pressure, Pimax (kPa) 6.39 (2.30) 6.57 (1.71) NS
Maximum expiratory pressure, Pemax (kPa) 12.6 (4.76) 12.2 (2.23) NS
Ventilatory parameters
Tidal volume, VT (l) 0.62 (0.14) 0.66 (0.18) NS
Respiratory rate (breaths/min) 21.1 (6.1) 19.1 (5.0) NS
Minute volume, VE (l/min) 14.4 (3.2) 14.5 (3.2) NS
Inspiratory time/total respiratory time, TI=TTOT (ratio) 0.38 (0.06) 0.39 (0.04) NS
Tidal volume/inspiratory time ratio, VT=TI (l/s) 106 (28.7) 107 (21.6) NS
Occlusion pressure, P0.1 (kPa) 0.48 (0.16) 0.45 (0.15) NS
Daytime arterial blood gases
Arterial oxygen tension, PaO2 (kPa) 7.45 (0.85) 8.54 (1.15) o0.05
Arterial carbon dioxide tension, PaCO2 (kPa) 6.65 (0.49) 5.38 (0.45) o0.05
DP0.1/DPaCO2 (kPa/kPa) 0.04 (0.11) 0.13 (0.18) o0.05
DVE=DPaCO2 (l/min/kPa) 3.75 (1.80) 5.85 (3.00) o0.05
Data as mean (SD).
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[12.7]%); and the FEV1/FVC ratio was 480% in all
cases. Tidal volume (VT), respiratory rate, inspira-
tory time and total breathing cycle length (TI=TTOT)
ratio showed a physiological pattern. P0.1 value
was slightly elevated (mean 0.47 [0.15] kPa). The
response of this parameter to hypercapnic stimulus
was low, with a mean relationship between the
change of P0.1 and that of PaCO2 (DP0.1/DPaCO2)
of 0.04 (0.11). Minute volume (VE) also did not
respond to the hypercapnic stimulus, with a mean
relationship between VE variation and PaCO2 varia-
tion (DVE/DPaCO2) of 3.76 (1.80) l/min/kPa.
All patients were ventilated with BiPAP positive
airway pressure ventilators, with a mean IPAP of 19
(2) cm H2O and EPAP pre-fixed at 5 cm of H2O. In all
patients, the duration of home mechanical ventila-
tion was greater than 4 h a day. Oxygen delivery
was not discontinued in the nine patients in whom
this therapy was needed at baseline. No patient
was withdrawn from the programme during the
study period.
Both daytime and nocturnal blood gases were
measured at baseline and at follow-up. At the end
of the study, there were significant changes in
PaO2, PaCO2, FVC and DP0.1/DPaCO2 and
DVE=DPaCO2 ratios (Table 1 and Fig. 1). On the
other hand, changes of PaCO2 and DP0.1/DPaCO2
ratio after hypercapnic stimulus correlated signifi-
cantly (Fig. 2). Individual values of arterial blood
gases and ventilatory response to hypercapnia
before and after 1-year of home mechanical
ventilation are shown in Table 2. All patients
showed an improvement in PaCO2 after treatment,
with values o6 kPa in all but one patient. A
significant reduction was also observed in the
bicarbonate value, going from 31.1 (2.8) at the
onset of the study to 26.9 (2.9) at 12 months.
However, no changes were observed in the pH
values at the onset (7.39 [0.03]) and end of the
study (7.40 [0.03]).
Discussion
The present results show that the use of non-
invasive home mechanical ventilation for 1-year
period in patients OHS resulted in improvements of
arterial blood gases, respiratory function and
ventilatory response to hypercapnia. It should be
noted that although patients had increased P0.1
values at baseline, a reduced response to hyper-
capnia was observed.
Home mechanical ventilation has already shown
to be of clinical value in OHS. It has been proved
that the use of this therapeutic modality manages
to improve gas exchange of patients with this
disease.12–14 Its efficacy in comparison with oxygen
therapy has been evaluated in a recent controlled
study, carried out in obese patients with nocturnal
hypoventilation and subjects with diseases of the
thoracic wall, most of them kyphoscoliotics.2 In
both groups of patients, significant improvement of
the symptoms derived from nocturnal hypoventila-
tion, elevation of the daytime PaO2 and reduction
of the nocturnal PaCO2 were demonstrated when
they were treated. This improvement has only been
observed with nocturnal non-invasive ventilation.
By contrast, little change was observed when
oxygen therapy, considered as standard treatment
up to this time, was used. In later studies, it was
confirmed that patients with OHS improved clini-
cally and functionally after treatment with non-
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Figure 1 Changes of daytime arterial blood gases and
ventilatory response to hypercapnia before and 1-year
after treatment with home mechanical ventilation.
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invasive ventilation.4 The improvement is similar to
that obtained in patients with kyphoscoliosis, a
disease in which non-invasive mechanical ventila-
tion has traditionally been shown to be very
effective.
In our study, we have also found that the use of
home mechanical ventilation is associated to an
improvement of arterial blood gas parameters. In
addition, an increase in ventilatory response
compared to hypercapnic stimulus has been ob-
served. Furthermore, it was also demonstrated that
after a period of treatment with the home
mechanical ventilation and after decrease of
PaCO2, the response of P0.1 to hypercapnia
becomes normalised, although it remains in the
low limit of normality. Response of VE to this
stimulation also improves significantly, although it
does not become normalised. These results seems
to add evidence to recovery of chemoreceptor
sensitivity as one of the benefits of non-invasive
ventilation. Similar results have been obtained in
other studies.15 Recovery of the respiratory centres
sensitivity would explain, at least partially, why
nocturnal ventilation not only improves gas ex-
change during the night but also produces an
arterial blood gas improvement at daytime.
On the other hand, it has been suggested that
home mechanical ventilation produces an im-
provement in pulmonary distensiblity, with disap-
pearance of the atelectatic areas, pulmonary
volumes and functioning of the respiratory mus-
cles.5 Pankow et al.16 have demonstrated that
non-invasive ventilation with positive pressure
can unload the inspiratory muscles of OHS patients.
In this study, we have found a significant increase
of FVC after treatment with home mechanical
ventilation. This improvement cannot be ex-
plained, as has previously been described,17 by a
reduction in body mass, since significant variations
of BMI during the follow-up period have not been
observed.
According to our results, it can be deduced that
the mechanism by ventilatory assistance exerts its
effect can be multifactorial. In this way, this
treatment could affect the possible pathogenic
mechanisms of OHS. In different studies, it has
been demonstrated that patients with this disease
show a decrease in ventilatory response to chemi-
cal stimulation, whether hypoxic or hypercapnic,
which means hyposensitivity of the respiratory
centres.18,19 In this study, poor response to hyper-
capnic stimulation was also observed, both when
measured by changes in P0.1 as well as by
variations in VE: Sampson and Grassino
20 have
suggested that this alteration could be one of the
causes of OHS, as no adequate compensation is
produced in risk situations. In any event, these
findings support the hypothesis that OHS is, at least
partially, due to a central alteration in the
ventilation control. According to this theory, it
has been demonstrated that many patients with
this disease can hyperventilate voluntarily until
their PaCO2 become normalised.
21 Along this same
line, it has been verified that the administration of
a respiratory stimulant such as progesterone to
patients with OHS is accompanied by normalisation
of PaCO2, as a consequence of an improvement in
the respiratory impulse, without any concomitant
alteration being produced in the ventilatory me-
chanics.22 On the other hand, in recent studies
carried out in rats it has been observed that deficit
or resistance to leptin, a hormone that acts on the
hypothalamus to suppress appetite, can play an
important role in the alteration of respiration
control.23,24 All these data point out to the
existence of a central mechanism that favours the
appearance of this disease.
In addition, mechanical factors have been in-
volved in the OHS aetiology. The reduction of the
thoracic compliance observed in these patients, as
a consequence of fat deposits on the thoracic wall,
leads to increase in the energetic output and
reduction of inspiratory muscular force, maximum
voluntary ventilation, maximum inspiratory pres-
sure and pulmonary volumes.25,26 However, the
weight loss in these patients is associated to an
increase in maximum voluntary ventilation and
forced vital capacity and a decrease in PaCO2, with
small variations of pulmonary distensibility.24 In
this study, no important effect on the respiratory
function tests has been detected. In addition, no
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significant correlation has been found between
body weight or BMI and the daytime hypercapnia.
With regard to the role played by sleep apnoea
syndrome in OHS, no causal relationship bet-
ween both conditions has been demonstrated up
to the present time. Although OHS may be
associated with obstructive sleep apnoea syndrome
it has been observed that there is an increased
prevalence of sleep-disordered breathing in pa-
tients with OHS.27 However, to avoid possible
confounding factors, patients OHS in which sleep-
disordered breathing was excluded by an overnight
cardiorespiratory polygraphy were only eligible for
our study.
Finally, the possibility that this disease has a
genetic component in the aetiopathogenesis has
been postulated. In some studies performed in
patients with asthma28 and COPD,29 it has been
demonstrated that there is a decrease in the
ventilatory response to hypercapnia in both the
patients as well as their first-degree relatives
compared to the normal population. However, in
a population of patients with OHS, differences in
ventilatory response to hypercapnia between pa-
tients, first-degree relatives and a group of healthy
subjects were not found.1 In our study, this aspect
was not evaluated.
In summary, non-invasive nocturnal ventilatory
assistance at home with BiPAP was an effective
approach for treating patients with OHS. Recovery
of sensitivity of the respiratory centres may be
postulated as a mechanism of arterial blood gas
improvement. However, despite of normalisation of
PaCO2 values, a poor ventilatory response was
obtained. This may suggest that an alteration of
central ventilatory control mechanisms may be
involved in the pathogenesis of OHS, although
the contribution of other factors remains to be
clarified.
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